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Abstract
Background: Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD),
the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper
clinical and prognostic assessment, but not all of them were validated in an international primary care cohort,
different from the original ones used for model development. Therefore, our main aim is to assess the prognostic
capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and
to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic
Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the
prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval
between them and to assess the impact on health of the patient’s lifestyle, social network and adherence to
treatment.
Methods: Design: External validation of scales, open and prospective cohort study in primary care.
Setting: 36 health centres in 6 European high, medium and low income countries.
Subjects: 477 patients diagnosed with COPD, captured in clinical visit by their General Practitioner/Nurse.
Predictors: Detailed patient history, exacerbations, lung function test and questionnaires at baseline.
Outcomes: Exacerbations, all-cause mortality and specific mortality, within 5 years of recruitment.
Analysis: Multivariate logistic regression and Cox regression will be used. Possible non-linear effect of the
indices will be studied by using Structured Additive Regression models with penalised splines. Subsequently,
we will assess different aspects of the regression models: discrimination, calibration and diagnostic precision.
Clinical variables modulated in primary care and the interval between exacerbations will be considered and
incorporated into the analysis.
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Discussion: The Research Agenda for General Practice/Family Medicine highlights that the evidence on predictive values
of prognostic indices in primary care is scarce. A prospective cohort like that of PROEPOC/COPD provides good
opportunities for research into COPD and make communication easier between family practitioners, nursing staff,
pneumologists and other professionals, supporting a multi-disciplinary approach to the treatment of these patients.
Trial registration: ISRCTN52402811. Date: 15/01/2015. Prospectively registered.
Keywords: Chronic obstructive pulmonary disease, Validation studies as topic, Primary health care, Prognosis
Background
Clinical and prognostic assessment of chronic obstructive
pulmonary disease
Chronic Obstructive Pulmonary Disease (COPD) is a
major public health problem, as there is considerable
underdiagnosis and a high morbimortality. It is the
fourth cause of death among males in European coun-
tries and its prevalence is expected to continue to in-
crease [1]. Available epidemiological data show a wide
variability in the incidence, prevalence and mortality in
different countries [2]. In Spain, the EPI-SCAN study [3]
found an overall prevalence for COPD of 10.2 % (CI
95 %: 9.2–11.1 %), higher among men than women
(15.1 %/5.6 %), with 4.4 % (CI 95 %: 3.8–5.1 %) of cases
classified as moderate to very severe (Stages II-IV of the
Global Initiative for Chronic Obstructive Lung Disease
[GOLD] classification).
COPD is characterized by a chronic poorly reversible
airflow limitation, which is usually progressive if appro-
priate measures are not taken. Although the value for
maximum forced expiratory volume in the first second
(FEV1) has been the most commonly used prognostic
variable, there is increasingly more evidence that FEV1
does not express the complexity and heterogeneity of
COPD. Exercise tolerance, exacerbations, comorbidity,
social support and quality of life are all dimensions that
have been shown to be important predictors of mortal-
ity, each with its own strengths and limitations [4]. This
has not led to abandoning the use of FEV1, with differ-
ent cut-off thresholds to the classic ones, as a simple
element with a high predictive value [5].
In its 2011 revised version, the GOLD [6] proposed a
combined assessment of COPD based on the patient’s level
of symptoms (measured on the modified Medical Research
Council [MRC] dyspnoea scale or the COPD Assessment
Test [CAT] questionnaire) and on the frequency of exacer-
bations in the last year or the degree of intensity of the ob-
struction (FEV1). This assessment has established the basis
for drawing up guidelines for the individualized therapeutic
management of COPD patients. Even though an advance, it
caused controversy: depending on the criteria used for the
classification, the allocation of patients could vary [7]; and
the prognostic capacity of each group has also varied in dif-
ferent studies [8, 9].
In 2012, the Guía Española de la EPOC (GesEPOC)
[the Spanish COPD guidelines, hereafter GesEPOC]
became available [10]. These clinical practice guidelines
classify COPD into 4 phenotypes: non-exacerbator, mixed
COPD-asthma, exacerbator with emphysema and exacer-
bator with chronic bronchitis. It also links the phenotypes
to the therapeutic activity, whether pharmacological
or not, but there is still no quantitative evidence re-
garding the relationship between prognostic variables
and each phenotype.
Therefore, the heterogeneous and systematic nature of
COPD has meant that, in recent years, numerous variables
are considered for its correct clinical and prognostic as-
sessment. This has led to the construction of different
multi-component or multi-dimensional scales. In a recent
systematic review, 15 indices were analysed [11], most had
a moderate to good prognostic value and some gave an
appropriate assessment. The BODE index [12] (B = Body
mass index; O = airflow Obstruction; D =Dyspnoea; and
E = Exercise capacity, the 6-minute walk test [6MWT])
has been the most widely used, even though the inclusion
of the 6MWT and the difficulty of incorporating this as-
pect for certain groups of patients limits its use in primary
care settings.
For use in Primary Care (PC), the requirements for an
index are [13]: a) it is simple to record and calculate; b)
its components should be easy to record and register; c)
its components should individually be clinically signifi-
cant; d) it should be able to predict severity, with quality
of life and mortality as outcomes; and e) it should pre-
dict future exacerbations and consumption of resources.
With these criteria, the following indices could be se-
lected for use in PC:
1. The ADO (Age, Dyspnoea, Obstruction) index,
derived from the BODE index in which age is
included and with a higher predictive value than the
original BODE; i.e., able to predict the probability of
a specific patient dying in the next 3 years [14].
Recently, this scale has been recalibrated [15] in a
very large cohort.
2. The BODEx index, a simplified version of BODE in
which the 6MWT is eliminated, substituting it with
exacerbations without losing predictive capacity [16].
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In the updated GesEPOC of 2014 [17], its use is
proposed as a guide for referring patients and for
selecting pharmacological treatment. This index is
well known in Spain, but to date has had only
limited use in the rest of Europe.
3. The DOSE (Dyspnoea, Obstruction, Smoking,
Exacerbation) index is the only one initially designed
in PC, and although it first focused on health
outcomes, its prognostic capacity has been
demonstrated for mortality [18, 19].
The ADO and BODEx indices were designed for large
cohorts in a hospital setting, in some cases with outpa-
tients. To be applied in a different care setting, their val-
idation is recommended, as has already been partially
done in some studies [20, 21]. For the designers of each
index, each one is applicable in primary care and each
one has the best prognostic capacity. Comparing pub-
lished studies, the BODEx [16] has an area under the
curve (AUC) of 0.75, which has been exceeded by the
modified ADO index [15] with an AUC of 0.80, while
the value for the AUC for DOSE was not published [18].
COPD is a preventable and treatable disease, which re-
quires a comprehensive approach in its assessment as well
as multi-professional care. In addition to the indices de-
scribed above, other aspects will be considered that are re-
lated to the health outcomes of the patient and to the
preventative and/or therapeutic actions [22] usually man-
aged by the patient and by primary care professionals. Such
aspects have repeatedly shown that the quality of life of a
patient can improve even without changes in functional pa-
rameters: a) Smoking and alcohol, with standardized tools
in research and clinical practice for measurement and edu-
cational intervention. b) Physical exercise: The International
Physical Activity Questionnaire (IPAQ) is the only one vali-
dated in Spanish and other languages, allowing inter-
national comparisons to be made. Nevertheless, there are
other measurements that can be used, which have demon-
strated the effect of exercise on health outcomes [23]. c) So-
cial aspects, such as social network and family support [24].
d) Pharmacological follow-up: There is an electronic
prescription-dispensing system within the electronic med-
ical record (EMR) that allows an assessment of the follow-
up of clinical guidelines and a comparison of the drugs
prescribed and those collected from the pharmacy by the
patient, as a measurement of adherence, essential for
control of the disease by the patients themselves [25].
e) Comorbidities: Whether they have an underlying
pathophysiological basis or are coincidental in time, co-
morbidities modulate and/or complicate the evolution of
the diseases. Therefore, we will analyse the generic Charl-
son Comorbidity Index [26] and the specific COMorbidi-
ties in Chronic Obstructive Lung Disease (COMCOLD)
index, which reflects the combined impact of five
important comorbidities from the perspective of the pa-
tients and complements existing comorbidity indices that
predict mortality [27].
The existence of the EMR makes it possible to incorp-
orate in the follow-up three key aspects that are novel in
prognostic studies: a) the interval of time between exac-
erbations (and not only their number); b) the existence
of exacerbations treated in an emergency primary care
setting (which could involve treatment of the acute
phase, but maintains the medication prior to patient dis-
charge, at present not counted as exacerbation); and c)
assessment of adherence.
To sum up, the ADO and BODEx indices validated pre-
dominantly in cohorts from hospital settings can have a
different prognostic capacity in a PC setting, due to the
differences in severity and other clinical and social charac-
teristics that depend on the setting in which patients are
treated. Therefore, we need to verify if the capacity of
these indices to discriminate and calibrate patients is
maintained when they are applied in primary care.
Besides, the ADO, BODEx and DOSE indices, ob-
tained in the PC setting, can show a different prognostic
capacity in each subgroup, according to the GOLD classi-
fication and for each phenotype according to the GesE-
POC classification. We expect that the prognostic capacity
is better in groups C and D of the GOLD classification
and in the exacerbator phenotypes of the GesEPOC, be-
cause these patients may be more widely represented in
the population treated in the hospital and have lower
intragroup variability. The prognostic capacity for the
GOLD subgroups will vary according to whether CAT or
MRC is used for their classification.
The aim of our study is to assess the prognostic cap-
acity of the ADO, BODEx and DOSE indices in primary
care, and to validate the models obtained in subgroups
of patients, classified by the new combined assessment
proposed in the revised GOLD methodology of 2011
and according to the phenotypes proposed in the up-
dated GesEPOC of 2014. Besides, we want to confirm
that the prognostic capacity of all indices increases if
the number of exacerbations is substituted by the
interval between them and to assess the impact on
health of the patient’s lifestyle, social network and ad-
herence to treatment.
Method/design
Design
Open, prospective and multi-centre validating and updat-
ing scales study. Patient recruitment started in February
2015 and will last until Dec 31th, 2016. The patients will
be followed for 5 years since their recruitment.
Standards of Reporting adhere to the SPIRIT 2013
Statement for protocols.
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Setting
Primary Care Centres, from Vigo Health Authority (Galicia,
Spain) and from Balearic Islands Health Authority (Balearic
Islands, Spain). Through these centres, doctors/nurses po-
tentially willing to participate were identified during na-
tional and international scientific meetings, both in Spain
(Aragón, Canarias, Cataluña) and other European countries
(Croatia, Bulgaria, Macedonia, Germany and Romania).
Subsequently, General Practitioners (GPs) and/or Nurses
were invited and informed by e-mail about the description
of the background and objectives of the study, as well as
the implications of their participation. There are 36 health
centres involved.
Study sites can be found in authors affiliations.
Subjects
Patients diagnosed with COPD. The eligibility criteria
for those studied were similar to those used in the ori-
ginal derivation of the models.
Inclusion criteria
a) patients with a moderate-severe obstruction, defined
by a FEV1 lower than 80 % of the expected post-
bronchodilator FEV in the presence of a FEV1
quotient/forced vital capacity (FVC) lower than
70 %, diagnosed with COPD
b) patients in a stable phase of COPD, clinically defined
as at least 6 weeks since the last exacerbation
c) acceptance to participate in the study by providing
written informed consent.
Exclusion criteria
a) patients diagnosed with cystic fibrosis, or bronchiectasis
that is clinically significant or of a different origin to
COPD (tuberculosis, childhood infections,
immunodeficiencies, and severe cognitive or
mobility impairment)
b) patients diagnosed with a severe chronic disease,
besides COPD (active malignancy, AIDS, heart
failure, severe kidney or liver failure, etc.).
Sample size
A validation study has a specific goal: quantifying the
performance of an existing model in other data. Sample
size requirements for validation studies are not well
understood, and there is a dearth of empirical evidence
to guide investigators. In some cases it is possible to
choose sample size on statistical grounds. We will focus
on the precision and accuracy of the performance mea-
sures in the new data.
To analyse the ROC curve for each index and the cor-
responding AUC, the size of the sample was calculated
using pROC package, free software available at https://
cran.r-project.org/. The formula used was: power.roc.test
(auc = 0.75, sig.level = 0.05, power = 0.9, kappa = 8).
The selected parameters considered were: a) mortality
estimated in 3 years to be 12.5 % [14], which is a propor-
tion of 1 exitus for every eight patients; b) 30 % of the
patients belong to subgroups A, C and D of the GOLD
classification [9], although there are discrepancies in this
proportion according to the study; c) the lowest AUC
described for the different indices is 0.75 [15, 17]; and d)
Type I error has been set at 5 % and the power of the
study at 90 %.
Under these assumptions, 477 patients need to be re-
cruited, of which 30 % should belong to groups A, C
and D, with the number of patients in group A = number
in group B = number in group C = 133 (15 deaths and
118 living after 3 years). Moreover, 10 % are added for
patients expected to be in group B and a further 10 %
for losses to the study. This figure will also be adequate
for the total number of patients, but not for those in
group B. Currently, there is no published prevalence for
the GesEPOC 2014 phenotypes, therefore, these sub-
groups cannot be estimated.
Patient recruitment
The healthcare professionals identified potentially eligible
cases, within their quota of assigned patients, through
electronic medical records review (10 per professional).
Those patients who are diagnosed with COPD will be in-
cluded, provided that they fulfil the inclusion criteria as
explained previously. After obtaining the informed con-
sent, patients will be incorporated in the study if they have
already been correctly diagnosed with COPD. The results
of a test taken in the last 6 months during a stable phase
will be considered valid; if the last test was more than
6 months ago, a new spirometry test will have to be taken.
The study personnel will assess whether the patients have
COPD stage II–IV using portable and hand-held spirom-
etry. For our purpose, we will determine postbronchodila-
tor FEV1 and Forced Vital Capacity as a measure for
airflow obstruction. Ten minutes before measuring lung
function, patients will inhale two puffs of 100 μg salbuta-
mol through a spacer. Once a diagnosis is established, the
severity of the obstruction is classified in relation to the
post-bronchodilator FEV1 value, expressed as a percent-
age of the expected level.
The undertaking of the spirometry test and its inter-
pretation will be the responsibility of specially trained
staff, who has taken an accredited and tutored theoret-
ical and practical course.
Outcome variables
Survival (time to event) without exacerbation will be
assessed during 5 years since patient recruitment. In
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addition, mortality (time to event) from all causes and
those specifically due to respiratory causes will be ana-
lysed as health outcome at the end of the study. Data
source will be EMR and death registry data if needed.
Blind assessment of the outcome to be predicted is not
feasible.
Exacerbations are defined as any sustained increase in
respiratory symptoms (dyspnoea, cough and/or expec-
toration) that require modification of the usual treat-
ment and/or hospital care -visit to the Emergency Room
or admission- (for the BODEx index), as well as the ex-
acerbations identified at the PC emergencies department
(but without changing subsequent treatment). In this
definition, admissions for pneumonia, pulmonary embol-
ism and other causes of complications in COPD are not
included.
Predictors
Assessment of predictors is done by GPs/nurses at base-
line, without knowledge of the participant’s outcome,
following the indices (ADO, BODEx, DOSE) definition.
Formulas to calculate them are available in Additional
file 1: Table S1.
They will be recorded in a specific database along with
detailed patient history: date of birth, sex, height, weight,
and body mass index. The spirometry test will be carried
out according to protocol recommendations and the
date of the first spirometric diagnosis of COPD will be
recorded. Dyspnoea will be assessed according to the
scale proposed by the British Medical Research Council for
the ADO and BODEx indices. Associated diseases will be
evaluated using the Charlson Comorbidity Index and
COMCOLD, and the presence of other relevant illnesses,
not included in Charlson, will be recorded, such as myop-
athy, osteoporosis, obstructive sleep apnoea-hypopnoea syn-
drome, and anxiety and depression disorders. The COPD
Assessment Test (CAT) questionnaire will be used to assess
the impact of COPD on the daily life and welfare of the pa-
tient, and its results will be used for categorisation accord-
ing to the revised 2011 GOLD classification. Participating
patients will be asked about tobacco consumption (packets/
year), alcohol consumption (yes/no, units/week), physical
exercise (Physical Activity Questionnaire short form (IPAQ),
daily physical activity intense/moderate/low), current re-
spiratory pharmacological treatment (in the stable phase),
influenza and pneumococcal vaccine status, having received
advice about their lifestyle and evaluation of the social sup-
port of the patient. The patient will be classified in accord-
ance with the phenotypes defined by the GesEPOC [17].
The number of exacerbations in the previous years will
be counted, in accordance with each index definition.
The ADO and modified ADO (from 0 to 14) indices,
the BODEx index, DOSE index, Charlson index, COM-
COLD index and the combined assessment of the GOLD
score using the four possible models will be automatically
calculated when introducing the variables that make up
the computerised database.
For clinical monitoring of the patient, but not included
in the prognosis model, a laboratory analysis must be car-
ried out and should include: haemogram, determination
of alpha-1-antitrypsin levels (if they have never been de-
termined), IgE and eosinophilia in sputum, as minor cri-
teria of GesEPOC. Moreover, if it is an initial diagnosis, a
chest radiograph will be requested. An electrocardiogram
will be required if pulmonary hypertension or Stages III or
IV of the GOLD classification are suspected [6].
Independent variables in the follow-up
The follow-up will be undertaken by clinical visits every
6 months. When the patient cannot make the appoint-
ment, follow-up will be by telephone interview or a re-
view of the EMR. Information about the date of clinical
exacerbations, admissions, visits to the emergency de-
partment (primary care or hospital) and mortality will be
obtained by a review of the patient’s medical record,
contact with the patient’s family and/or passive follow-
up (from hospital and mortality records). Survival will
be evaluated after 5 years. If cases are referred to a sec-
ond care level, any specialist care appointments will be
recorded.
Adverse events and dropouts during follow-up will be
recorded, with the reason for them.
Participant time line
At enrolment, a clinical assessment is performed for all
the patients by appropriately trained study personnel. Par-
ticipants are asked to perform spirometry and complete
the study questionnaires (Table 1). Participants are also re-
quested a laboratory analysis and chest radiograph if
needed following the GOLD guideline. Every 6 months,
their exacerbations will be count up.
In terms of the level of additional risk posed by diag-
nostic/monitoring procedures as compared to normal
clinical practice, these will be performed in accordance
with the terms of the treatment guidelines [1] in any
Member State concerned.
Data analysis
The analyst will identify incomplete data and communi-
cate it to the relevant professional for the particular pa-
tient. Appropriate test and statistical treatment (multiple
imputations) of lost values will be performed.
To assess the discriminatory capacity of the different in-
dices studied (ADO, BODEx and DOSE), logistic regression
models and Cox proportional hazard models will be con-
structed. Initially, the possible non-linear effect of the indi-
ces will be studied by using Structured Additive Regression
(STAR) models with penalised splines. Subsequently, we
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will assess different aspects of the regression models: dis-
crimination, calibration and diagnostic precision. For cali-
bration, the Brier score will be used, together with the
Hosmer–Lemeshow test for goodness of fit and graphs of
the non-parametric estimates of the association between
the expected frequencies and those found for the model.
To determine the discrimination of the models, ROC
curves (and the corresponding AUC) will be calculated.
For survival models, the time-dependent ROC will be esti-
mated, as well as its graphical representation. Diagnostic
precision will be calculated as the proportion of patients
classified incorrectly. For this purpose, the classification
rule shall be as follows: each patient will be classified as be-
longing to the group for which the predicted probability is
higher. To correct against optimism, bootstrap techniques
will be used.
Statistical analyses will be carried out using BayesX
software for the Structured Additive Regression (STAR)
models, freely accessible at http://www.statistik.lmu.de/
~bayesx/bayesx.html the packages rms, survival, surv2-
sampleComp, pROC, risksetROC of software R [28, 29],
available free at http://cran.r-project.org.
Discussion
COPD in Europe affects between 4 and 10 % of adults
and causes between 200,000 and 300,000 deaths annu-
ally. Moreover, associated healthcare costs are estimated
at around 10,000 million Euros. The European Platform
of Public Health Organizations (EPHA) recommended
that COPD research should be included among the pri-
ority objectives included in Horizon 2020. Moreover,
strategy B3 of the European Innovation Partnership on
Active and Healthy Aging prioritised COPD among the
chronic diseases requiring research.
The Research Agenda for General Practice/Family
Medicine [30] of the European General Practice Re-
search Network (EGPRN) established recommendations
both for objectives and methodologies coherent with Fam-
ily Medicine as defined by World Organization of Na-
tional Colleges, Academies and Associations of General
Practitioners/Family Physicians (WONCA). This agenda
has been translated by members of our research team to
orientate the research strategy in PC in Spain. The Re-
search Agenda highlights that the evidence on predictive
values of all kinds of findings, test or prognostic indices in
primary care settings is scarce. Many tests have not been
formally evaluated in primary care; different prevalence
settings are then used, with more or less selected popula-
tions, and often result in unrealistically high prevalence
estimates for chronic disease. This is problematic as these
results are then used to conclude that GPs are not good at
detecting disease and many articles then recommend indi-
ces for prognosis in unselected populations or to identify
patients to be treated.
In this context, a prospective cohort like that of PROE-
POC/COPD provides good opportunities for learning
about the clinical course of COPD in a PC population,
which represents all patients with COPD, from the mildest
to the most severe cases. Considering the characteristics
of the initial cohort, and the higher survival expected in a
primary care setting, ADO and BODEx recalibration may
be necessary, as had to be done to combine the cohorts of
international studies [15]. The International Primary Care
Respiratory Group (IPCRG) set up the Uncovering and
Table 1 Participants time line
2014 2015 2016 2015–2021
Planning
WHAT
Design x
Galician Ethics Committee
approval
x
Other nodes Ethics Committees x x
Funding x x
Web-page design and pilot study x
WHO (nodes)
Galicia x
Balearic Islands x
Recruitment
WHAT
Spirometry x
Clinical assesment x
MRC x
CAT x
IPAQ x
Laboratory analysis (optional) x
Chest radiography (optional) x
WHO (nodes)
Galicia x
Balearic Islands x
Aragon x
Canary Islands x
Catalonia x
Bulgaria x
Croatia x
Germany x
Macedonia x
Romania x
FOLLOW-UP
WHAT
Exacerbations (type and number) x x x
Mortality and morbidity outcome x x x
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Noting Long-term Outcomes in COPD and asthma to en-
hance Knowledge (UNLOCK) cohort [31]. Kruis [32] eval-
uated the external validity of 6 large pharmaceutically-
sponsored COPD studies (LPCS) and compared them to
the characteristics of the patients in 7 database registers
that constitute the UNLOCK cohort: between 53 and
84 % of the patients treated in primary care did not fulfil
the inclusion criteria of the cohorts recruited in the hos-
pital setting.
In this study, prognostic indices (ADO, BODEx and
DOSE) will be assessed for COPD, in different sub-
groups of patients. Therefore, it will influence the func-
tioning of the health system, because the classification of
COPD patients will individualize preventative activities
and/or treatments indicated for each patient, modify re-
ferral procedures between general family practitioners-
nursing staff and specialty-primary care and improve
knowledge/self-management of the disease by patients
themselves and their families.
The good technical quality of the information obtained is
essential for the results of the study to be valid and to re-
duce variability. Standardization of protocols, including
web-page form were sent to the researchers, reviewed and
translated in each country by the node leaders. Group re-
unions are planned during EGPRN meetings, twice per
year. The study protocol was presented and reviewed at
Barcelona meeting, 11st May, 2014. Later, three reunions
were organized (Heraklion, Timisoara and Edirne). The
project was presented at UNLOCK board during Singapore
IPCRG meeting in 2015. For quality control, the following
procedures will be in place throughout the different stages
of the study in each node: daily calibration of spirometers;
automation of filter variables and forms; computer-based
administration of questionnaires; accreditation of the train-
ing of the nursing staff in spirometry; updating of clinical
knowledge about COPD, data monitoring three times per
year. An international workshop about spirometry was or-
ganized during WONCA Istanbul meeting in 2015 and
web seminars will be scheduled (one per year).
TRIPOD Group [33] encourages complete and trans-
parent reporting reflecting study design and conduct,
and even enter the study in registers that accommodate
observational studies such as ISRCTN. We try to help
readers submitting the TRIPOD reporting template as
Additional file 1: Table S2.
The information gathered will allow research into
COPD and make communication easier between family
practitioners, nursing staff, pneumologists and other pro-
fessionals, supporting a multi-disciplinary approach to the
treatment of these patients. Both GOLD and the pheno-
types recently presented in the updated GesEPOC have
this same orientation. Soriano [34] compared the different
groups of combined assessment and the predictive validity
of the old and new GOLD methodologies, speculating that
there may be a higher percentage of type B COPD in pri-
mary care and, therefore, the need for a longer follow-up
period. The GesEPOC 2014 uses prognostic indices
(BODEx, with 5 as the cut-off threshold) to refer patients
[17].
The UNLOCK cohort has demonstrated the superior-
ity of DOSE over ADO. However, in a primary care-
based cohort, no study in a European setting has
included the BODEx index in the comparative analysis.
The main aim of the present study, and one of its contri-
butions to this debate, is to undertake a comparative
analysis among these indices and with DOSE, in the
same patients and with common recruitment criteria.
Moreover, the PROEPOC/COPD study gives priority to
issues about preventative and/or therapeutic actions
usually managed by the patient and by primary care pro-
fessionals that should be tackled in that setting.
The usefulness of these indices will be determined by
their application in primary care [35] and the possibility
of personalized treatment, as has been established for a
considerable time for cardiovascular diseases. Multi-
dimensional scales are tools that should be analysed and
used in relation to these guidelines [36].
Additional file
Additional file 1: Table S1. Calculation of the indices. Table S2.
TRIPOD Checklist: Prediction Model Validation (DOCX 27 kb)
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(Spanish guide for chronic obstructive lung disease); GOLD: Global initiative for
chronic obstructive lung disease; GP: General practitioner; IPAQ: International
physical activity questionnaire; IPCRG: International primary care respiratory group;
MRC: Medical research council; PC: Primary care; STAR: Structured additive
regression; UNLOCK: Uncovering and noting long-term outcomes in COPD and
asthma to enhance knowledge; WONCA: World Organization of National Colleges,
academies and associations of general practitioners/family medicine
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